MyMD Pharmaceuticals (MYMD) Competitors $0.12 -0.02 (-11.52%) As of 07/25/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFDA EventsInsider TradesOptions ChainSEC FilingsTrendsBuy This Stock MYMD vs. PTPI, TRVN, PBLA, HEPA, BPTSY, SYRS, VIRX, NCNA, VINC, and CAPSShould you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Petros Pharmaceuticals (PTPI), Trevena (TRVN), Panbela Therapeutics (PBLA), Hepion Pharmaceuticals (HEPA), Biophytis (BPTSY), Syros Pharmaceuticals (SYRS), Viracta Therapeutics (VIRX), NuCana (NCNA), Vincerx Pharma (VINC), and Capstone Therapeutics (CAPS). These companies are all part of the "pharmaceutical products" industry. MyMD Pharmaceuticals vs. Its Competitors Petros Pharmaceuticals Trevena Panbela Therapeutics Hepion Pharmaceuticals Biophytis Syros Pharmaceuticals Viracta Therapeutics NuCana Vincerx Pharma Capstone Therapeutics Petros Pharmaceuticals (NASDAQ:PTPI) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations. Is PTPI or MYMD more profitable? Petros Pharmaceuticals' return on equity of -78.22% beat MyMD Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Petros PharmaceuticalsN/A -78.22% -23.50% MyMD Pharmaceuticals N/A -179.05%-108.14% Do insiders & institutionals believe in PTPI or MYMD? 12.3% of Petros Pharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are held by institutional investors. 12.3% of Petros Pharmaceuticals shares are held by insiders. Comparatively, 2.1% of MyMD Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Which has higher earnings and valuation, PTPI or MYMD? MyMD Pharmaceuticals has lower revenue, but higher earnings than Petros Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPetros Pharmaceuticals$5.11M0.19-$8.16M-$60.870.00MyMD PharmaceuticalsN/AN/A-$4MN/AN/A Does the media favor PTPI or MYMD? In the previous week, Petros Pharmaceuticals' average media sentiment score of 0.00 equaled MyMD Pharmaceuticals'average media sentiment score. Company Overall Sentiment Petros Pharmaceuticals Neutral MyMD Pharmaceuticals Neutral Which has more volatility & risk, PTPI or MYMD? Petros Pharmaceuticals has a beta of 1.56, indicating that its share price is 56% more volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.15, indicating that its share price is 115% more volatile than the S&P 500. SummaryPetros Pharmaceuticals beats MyMD Pharmaceuticals on 5 of the 7 factors compared between the two stocks. Get MyMD Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MYMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MYMD vs. The Competition Export to ExcelMetricMyMD PharmaceuticalsDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$277K$19.95M$5.69B$9.50BDividend YieldN/AN/A4.58%4.01%P/E RatioN/AN/A28.1020.05Price / SalesN/A22.04432.4490.07Price / CashN/AN/A36.2258.56Price / Book0.020.028.665.87Net Income-$4M-$15.34M$3.25B$258.55M7 Day PerformanceN/A11.11%4.23%3.74%1 Month Performance-15.12%-8.83%10.52%11.75%1 Year Performance-93.92%-47.22%34.41%18.03% MyMD Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MYMDMyMD PharmaceuticalsN/A$0.12-11.5%N/A-92.9%$277KN/A0.006Gap DownHigh Trading VolumePTPIPetros PharmaceuticalsN/A$0.03-1.7%N/A-99.7%$913K$5.11M-0.0120Gap DownTRVNTrevena1.1673 of 5 stars$0.91flat$5.00+449.5%-84.0%$873K$443K-0.0240PBLAPanbela Therapeutics0.2989 of 5 stars$0.16-1.3%N/A-53.1%$767KN/A0.006HEPAHepion Pharmaceuticals0.1279 of 5 stars$0.06+20.0%N/A-99.9%$656KN/A-0.0120Gap UpBPTSYBiophytisN/A$1.81flatN/AN/A$634KN/A0.0030Gap UpSYRSSyros Pharmaceuticals4.1419 of 5 stars$0.02flat$3.33+16,566.7%-99.8%$537K$386K-0.01120News CoverageUpcoming EarningsGap DownVIRXViracta Therapeutics2.5622 of 5 stars$0.01flat$1.75+17,793.7%N/A$389KN/A-0.0120NCNANuCana3.318 of 5 stars$0.05-0.2%$25.00+47,159.0%-98.3%$320KN/A-0.0130Gap UpHigh Trading VolumeVINCVincerx Pharma2.4891 of 5 stars$0.05-9.3%$40.00+77,269.4%-99.6%$271KN/A0.0060Gap DownCAPSCapstone TherapeuticsN/A$1.69+5.6%N/AN/A$270K$44.88M0.0038 Related Companies and Tools Related Companies PTPI Alternatives TRVN Alternatives PBLA Alternatives HEPA Alternatives BPTSY Alternatives SYRS Alternatives VIRX Alternatives NCNA Alternatives VINC Alternatives CAPS Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MYMD) was last updated on 7/26/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredTrump's 2025 Economic Revolution Is Here Are Your Retirement Savings Ready?Time is short. Trump's reforms may be coming fast—and the financial system roller coaster may be a ride that y...Create New Advertiser | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…GoldCo Precious Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MyMD Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share MyMD Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MYMD Stock Alerts